Pricing Log in Create free account
Friday 6 November 2026 Export SKIN’s income statement to Excel — free account

SkinHealth Systems Inc.

SKIN Consumer Defensive Household & Personal Products

SkinHealth Systems Inc.’s revenue for fiscal 2025 (year ended December 2025) was $300.8 million, down 10.0% from fiscal 2024.

Revenue
−2.10%
EPS
−112.5%
Free cash flow
+19.1%
Total debt
−33.1%

Quarter to September 2026, against a year earlier

14.76 4.41 +42.61%
Market cap
$67.4M
P/E
0.0×
Fwd P/E
−3.1×
Dividend yield
—
F-score
6/9
Altman Z
−0.45
Beneish M
−3.05
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 38.42%

Capital & Financial Ratios $m

Size
Market Cap 67.35
Revenue ttm 288.56
Net income ttm (18.29)
Free cash flow ttm 18.28
Net debt Q 130.58
Valuation
P/E 0.00
Forward P/E (3.12) (negative: loss-making)
Price / sales 0.23
Forward P/S Powerpack
Price / FCF 3.70
Price / book 1.21
Financial health
Current ratio Q 2.89 (at or above 1.5: strong)
Debt / equity Q 4.36 (above 2: weak)
Interest coverage Q 0.79
Growth
Revenue growth Q −2.10% (below 0%: shrinking)
Operating income growth Q +179.75% (above 0%: growing)
EPS, this year −97.97% (below 0%: weak)
EPS, next year A +68.25% (at or above 15%: strong)
Revenue, next year A −5.28% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +35.72% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.0×, against a ten-year median of 1.5×; over the ten years it ranged from 0.8× in 2026 to 16.8× in 2021.
P/S against its own 10 years 0.45%
10-year low 10-year high
P/B against its own 10 years 0.44%
10-year low 10-year high
EV/Sales against its own 10 years 16.88%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 523 370 233 112
Receivables 55 28 23 20
Inventory 91 69 48 46
Other — — — —
698 477 310 202
2023 2024 2025 Q'26
Payables 45 22 16 15
ST’ Debt — — 124 —
Other 21 — — —
115 68 186 70

Compound Annual Growth %

10y 5y 3y
Sales — 20.36% (6.32%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% (28.50%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.80 Actual −0.40

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −1.60 −1.80 Miss by 0.20
Q4 FY25 −1.40 −1.20 Beat by 0.20
Q1 FY26 −1.80 −1.00 Beat by 0.80
Q2 FY26 −0.80 −0.40 Beat by 0.40
Q3 FY26 −1.32 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (1.00) (0.40) — — —
’25 (1.60) 2.81 (1.80) (1.20) (1.40)
’24 (0.09) 0.03 (3.00) (1.60) (4.60)
’23 (3.40) 0.60 (11.20) (1.40) (15.20)
’22 4.12 0.83 (0.01) 1.01 5.96
’21 (1.84) (30.40) (32.60) (2.40) (73.40)
’20 — (6.03) (1.25) (0.40) (17.01)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 65 72 69 — —
’25 70 78 71 82 301
’24 81 91 79 83 334
’23 86 117 97 97 398
’22 75 104 89 98 366
’21 48 67 68 78 260
’20 — 14 35 — 119
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (6) 3 11 — —
’25 3 10 10 15 37
’24 (17) 6 10 16 16
’23 (13) 22 18 (5) 22
’22 (38) (31) (31) (5) (107)
’21 1 (33) 0 3 (28)
’20 — (12) 0 (1) (12)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (7) 1 10 — —
’25 2 8 9 14 32
’24 (19) 4 8 16 9
’23 (35) 19 14 (7) (10)
’22 (42) (36) (39) (8) (125)
’21 0 (37) (2) (5) (44)
’20 — (13) (2) (1) (16)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3.2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — 167 119 260 366 398 334 301 289 +10.3% 285 295 307 +0.7%
Gross margin, % — — — 63.92 56.43 68.65 68.00 38.97 54.53 65.28 67.22 +1.4 pt
EBT — — — (3) (38) (381) 45 (102) (30) (6) (13) +12.5%
EBT margin, % — — — (1.76) (32.31) (146.35) 12.39 (25.60) (8.84) (1.97) (4.57) (0.2) pt
Net income — 0 — (2) (29) (379) 44 (100) (29) (10) (18) n/m
Per share, $
Per share, $ Revenue — — — 103.70 69.45 50.94 49.59 60.45 53.99 47.60 0.00 (12.2%)
Earnings — — — (1.02) (17.01) (73.40) 6.00 (15.20) (4.60) (1.60) (4.40) +7.8%
Cash flow — — — 1.08 (7.25) (5.55) (14.45) 3.30 2.61 5.93 0.00 +32.9%
Capex — — — (6.49) (2.23) (3.06) (2.56) (4.79) (1.10) (0.82) 0.00 (29.2%)
Free cash flow — — — (5.41) (9.48) (8.61) (17.01) (1.48) 1.51 5.12 0.00 n/m
Book value — — — 0.00 (17.47) 59.21 22.64 9.02 8.37 9.66 0.00 n/m
Shares, m — — — 2 2 5 7 7 6 6 6 +25.6%
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 28.91 0.00 0.00 0.00 0.00 4.1
P/S — — — 0.00 0.00 9.49 3.72 1.02 0.59 0.58 0.23 2.2
P/B — — — 16,325.50 130.07 8.16 8.14 6.85 3.80 2.88 1.21 2,355.1
EV/Sales — — — 0.00 0.00 8.84 4.19 1.58 1.15 1.02 1.04 2.4
EV/FCF — — — 0.00 (75.84) (52.28) (12.22) (64.29) 41.12 9.51 16.48 (22.0)
Cash, $m
Cash, $m Operating cash flow — — — 2 (12) (28) (107) 22 16 37 24 +67.0%
Capex — — — (10) (4) (16) (19) (32) (7) (5) (5) (11.0%)
Free cash flow — — — (9) (16) (44) (125) (10) 9 32 18 n/m
Balance, $m
Balance, $m Working capital — — — — 28 924 712 583 409 123 132 +34.3%
Net debt — — — — 207 (168) 173 215 182 132 131 (8.6%)
Shareholders’ equity — — — — (30) 302 167 59 52 61 56 n/m
Returns, %
Returns, % ROA — — — 0.00 (26.19) (52.55) 3.98 (10.36) (3.60) (1.61) (4.10) (1.6) pt
ROIC — — — 0.00 (6.06) (18.58) (4.75) (29.78) (18.11) (6.74) 2.32 (6.7) pt
ROE — — — 0.00 (21.45) (278.16) 18.84 (88.42) (52.34) (16.87) (30.13) (16.9) pt
People
People Employees — — — — 2 704 1,034 881 769 613 — +214.3%
Revenue/emp, $m — — — 0.00 59.55 0.37 0.35 0.45 0.43 0.49 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

SkinHealth Systems Inc. vs peers in Household & Personal Products (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ACU Acme United Corporation. $263.9M 26.9× 25.5× +16.15% (above 0%: growing) +4.76% (above 0%: growing) +155.61% (above 0%: growing) 42.55% 10.89% Compare
NUS Nu Skin Enterprises, Inc. $220.5M — (loss-making) — (loss-making) −17.10% (below 0%: shrinking) n/m −86.06% (below 0%: shrinking) 68.20% (18.53%) Compare
YSG Yatsen Holding Limited Sponsored ADR $118.0M — (loss-making) — (loss-making) +10.97% (above 0%: growing) n/m +14.56% (above 0%: growing) 73.88% (11.55%) Compare
SKIN SkinHealth Systems Inc. $67.4M — (loss-making) — (loss-making) −2.10% (below 0%: shrinking) n/m +19.12% (above 0%: growing) 68.16% 7.20%
SLSN Solesence, Inc. $61.2M — (loss-making) — −24.69% (below 0%: shrinking) n/m +86.52% (above 0%: growing) 30.97% 0.79% Compare
GROV Grove Collaborative Holdings, Inc. $44.8M — (loss-making) — (loss-making) −16.94% (below 0%: shrinking) n/m +101.08% (above 0%: growing) 53.56% (2.14%) Compare
UG United-Guardian, Inc. $31.2M 12.6× 18.7× +9.52% (above 0%: growing) +14.29% (above 0%: growing) +428.43% (above 0%: growing) 49.73% 24.26% Compare
DSY Big Tree Cloud Holdings Limited $15.4M 17.8× — — 0.00% −267.22% (below 0%: shrinking) — — Compare
ATTT Atlas Trinity Tech Limited $11.9M — — — — −192.00% (below 0%: shrinking) — — Compare
Median of peers $53.0M 17.8× — −3.71% +4.76% +50.54% 51.65% (0.67%)

All 30 Household & Personal Products stocks →

Pay and ownership Proxy statement filed 12 August 2026

Ownership

Directors and executive officers, together 35.50%
Brian Miller 25.80%
LCP Edge Holdco LLC 25.60%
Capricorn Fund Managers Ltd 17.10%
Brenton L. Saunders 8.20%
FMR LLC 7.80%
BlackRock Portfolio Management LLC 5.50%
Integrated Core Strategies (US) LLC 5.00%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

SkinHealth Systems Inc. (SKIN) Latest News

6 Nov

Impact 3 · · The Motley Fool transcript
Impact 3 · · GuruFocus.com transcript

5 Nov

Impact 3 · · GlobeNewswire

29 Oct

Impact 4 · · Zacks
Impact 3 · · Simply Wall St.

22 Oct

Impact 3 · · GlobeNewswire

16 Oct

Impact 3 · · Zacks

9 Oct

Impact 4 · · GlobeNewswire

6 Oct

Impact 4 · · GlobeNewswire

1 Oct

Impact 4 · · GlobeNewswire

15 Sep

Impact 3 ·

8 Sep

Impact 4 ·

26 Aug

Impact 4 ·

11 Aug

Impact 3 ·

7 Aug

Impact 4 · · Moby transcript
Impact 4 ·
Impact 3 · · MarketBeat

6 Aug

Impact 4 ·
Impact 4 ·
Impact 3 ·

30 Jul

Impact 4 ·

14 Jul

Impact 3 ·

7 Jul

Impact 4 ·

7 Jun

Impact 4 · · Simply Wall St.

2 Jun

Impact 4 · · GlobeNewswire

12 May

Impact 3 · · Zacks

8 May

Impact 4 · · MarketBeat
Impact 3 · · Moby transcript

7 May

Impact 4 · · Zacks
Impact 3 · · Zacks
stockrow.com/SKIN · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com